Sanofi ( SAN:CA) Evercore 8th Annual Healthcare Conference December 2, 2025 11:30 AM EST Thank you guys for being here. Pleasure to have the CEO of Sanofi, but even more importantly, Chairman-elect of ...
To meet this challenge head-on, University of California San Diego researchers and clinicians are tackling Alzheimer’s at every angle — from the earliest detection to groundbreaking therapies, novel ...
The U.S. Food and Drug Administration announced the approval of the first hematopoietic stem cell transplant therapy to treat ...
In November 2025, the U.S. Food and Drug Administration (FDA) issued several approvals across oncology and supportive care.
The U.S. Food and Drug Administration has approved Itvisma (onasemnogene abeparvovec-brve) for the treatment of spinal ...
Zevaskyn, the first gene therapy for recessive dystrophic epidermolysis bullosa, showed significant wound healing in phase 3 ...
U.S. health regulators informed senior executives at Merck, Sanofi and AstraZeneca last week that their approved protective RSV treatments for infants would face fresh safety scrutiny following ...
The US FDA is advancing the drug approval process for sibeprenlimab, a novel targeted drug to help manage immunoglobulin A nephropathy (IgAN).
The FDA has granted traditional approval to Darzalex Faspro in combination with bortezomib, cyclophosphamide, and dexamethasone for the treatment of adults with newly diagnosed light chain amyloidosis ...
Pirtobrutinib is now FDA-approved for relapsed/refractory CLL/SLL after prior covalent BTK inhibitor therapy, following its 2023 accelerated approval. The BRUIN-CLL-321 trial showed pirtobrutinib ...
With a fresh FDA endorsement for its drug plozasiran, California-based Arrowhead Pharmaceuticals has successfully broken through to the commercial realm. Complicating the matter, however, is the fact ...
“It was a really hard sell,” recalls Druker, an oncologist and CEO of the Oregon Health & Science University Knight Cancer Institute, decades on. There were seemingly valid concerns at the time, he ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback